Jazz Pharmaceuticals (JAZZ) Reports In-Line Q4 EPS, FY Guidance Comes in Light

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.60, in-line with the analyst estimate of $2.60. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $349.83 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2016 EPS of $10.90-$11.30, versus the consensus of $11.42. Jazz Pharmaceuticals sees FY2016 revenue of $1.490-1.550 billion, versus the consensus of $1.54 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• The LGL Group (LGL) Misses Q2 EPS by 8c
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c